Optimising the Patient Journey in Chronic Spontaneous Urticaria

Chairperson:

Marcus Maurer¹

Speakers:

Clive Grattan,² Donald E Stull,³ Ana Giménez-Arnau⁴

1. Charité – Universitätsmedizin Berlin, Germany 
2. Norfolk & Norwich University NHS Foundation Trust, Norwich; St John’s Institute of Dermatology, London, UK 
3. Data Analytics and Design Strategy, RTI Health Solutions, Manchester, UK 
4. Hospital del Mar, Parc de Salut Mar, Universitat Autonoma, Barcelona, Spain

Disclosure:

Prof Maurer has received research funding and/or honoraria for consulting/lectures from Almirall, Essex Pharma, Genentech, JADO Technologies, Merckle Recordati, Moxie, Novartis, Sanofi Aventis, Schering-Plough, Merck, MSD, UCB, and Uriach. Dr Grattan has consultancies with GSK, Genentech, Novartis, and CSL Behring. Dr Stull is employed by RTI Health Solutions, which provides consulting and other research services to pharmaceutical, device, government, and non-government organisations. As an employee of RTI-HS, Dr Stull works with a variety of companies and organisations. No payment or honoraria are received directly from these organisations for services rendered. Prof Giménez-Arnau is a Medical Advisor for Uriach Pharma, Genentech, and Novartis; has received research grants supported by Intendis – Bayer, Uriach Pharma, and Novartis; and has educational activities sponsored by Uriach Pharma, Novartis, Genentech, Menarini, GSK, MSD, and Almirall.

Acknowledgements:

Writing assistance provided by Dr Saroshi Amirthalingam, Apothecom Scopemedical Ltd.

Support:

The publication of this article was funded by Novartis. The views and opinions expressed are those of the authors and not necessarily of Novartis.

Citation:

EMJ Dermatol. 2014;2[1]:35-40. DOI/10.33590/emjdermatol/10314250. https://doi.org/10.33590/emjdermatol/10314250.

Each article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.